176 related articles for article (PubMed ID: 29679262)
1. Serum osteoprotegerin levels and mammographic density among high-risk women.
Moran O; Zaman T; Eisen A; Demsky R; Blackmore K; Knight JA; Elser C; Ginsburg O; Zbuk K; Yaffe M; Narod SA; Salmena L; Kotsopoulos J
Cancer Causes Control; 2018 Jun; 29(6):507-517. PubMed ID: 29679262
[TBL] [Abstract][Full Text] [Related]
2. Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Odén L; Akbari M; Zaman T; Singer CF; Sun P; Narod SA; Salmena L; Kotsopoulos J
Oncotarget; 2016 Dec; 7(52):86687-86694. PubMed ID: 27893411
[TBL] [Abstract][Full Text] [Related]
3. Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women.
Toriola AT; Appleton CM; Zong X; Luo J; Weilbaecher K; Tamimi RM; Colditz GA
Cancer Prev Res (Phila); 2018 Dec; 11(12):789-796. PubMed ID: 30352839
[TBL] [Abstract][Full Text] [Related]
4. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
5. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
6. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
7. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
8. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
Sarink D; Schock H; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Arveux P; Fournier A; Kvaskoff M; Boeing H; Karakatsani A; Trichopoulou A; La Vecchia C; Masala G; Agnoli C; Panico S; Tumino R; Sacerdote C; van Gils CH; Peeters PHM; Weiderpass E; Agudo A; Rodríguez-Barranco M; Huerta JM; Ardanaz E; Gil L; Kaw KT; Schmidt JA; Dossus L; His M; Aune D; Riboli E; Kaaks R; Fortner RT
BMC Cancer; 2018 Oct; 18(1):1010. PubMed ID: 30348163
[TBL] [Abstract][Full Text] [Related]
9. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.
Oh ES; Rhee EJ; Oh KW; Lee WY; Baek KH; Yoon KH; Kang MI; Yun EJ; Park CY; Choi MG; Yoo HJ; Park SW
Metabolism; 2005 Jan; 54(1):49-54. PubMed ID: 15562379
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
[TBL] [Abstract][Full Text] [Related]
12. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
13. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
14. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
15. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
16. Hormone and receptor activator of NF-κB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.
Mintz R; Wang M; Xu S; Colditz GA; Markovic C; Toriola AT
Breast Cancer Res; 2022 Apr; 24(1):28. PubMed ID: 35422057
[TBL] [Abstract][Full Text] [Related]
17. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
19. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
Karalazou P; Ntelios D; Chatzopoulou F; Fragou A; Taousani M; Mouzaki K; Galli-Tsinopoulou A; Kouidou S; Tzimagiorgis G
Ital J Pediatr; 2019 Dec; 45(1):161. PubMed ID: 31823791
[TBL] [Abstract][Full Text] [Related]
20. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
Sarink D; Schock H; Johnson T; Overvad K; Holm M; Tjønneland A; Boutron-Ruault MC; His M; Kvaskoff M; Boeing H; Lagiou P; Papatesta EM; Trichopoulou A; Palli D; Pala V; Mattiello A; Tumino R; Sacerdote C; Bueno-de-Mesquita HBA; van Gils CH; Peeters PH; Weiderpass E; Agudo A; Sánchez MJ; Chirlaque MD; Ardanaz E; Amiano P; Khaw KT; Travis R; Dossus L; Gunter M; Rinaldi S; Merritt M; Riboli E; Kaaks R; Fortner RT
Cancer Prev Res (Phila); 2017 Sep; 10(9):525-534. PubMed ID: 28701332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
